Drug Trial Radar · NCT04517149
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Actual
Start
Jun 9, 2020
Primary completion
Jun 2026
Study completion May 2029
Sponsor
- Lead sponsor
- 4D Molecular TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR).
Conditions
- X-Linked Retinitis Pigmentosa
Interventions
4D-125 IVT InjectionBiological
4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
ObservationalOther
Natural History
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parametersTime frame: 24 months to 60 Months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado
Aurora, Colorado
Vitreo Retinal Associates
Gainesville, Florida
University of Michigan Kellogg Eye Center
Ann Arbor, Michigan
Columbia University Medical Center/Edward Harkness Eye Institute
New York, New York
Duke University Eye Center/Dept. of Ophthalmology
Durham, North Carolina
Casey Eye Institute, Oregon Health and Science University
Portland, Oregon
Retina Foundation of the Southwest
Dallas, Texas
University of Utah John A. Moran Eye Center
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.